AbbVie Calls Off Early-Stage Trial For I-Mab’s CD47-Targeted Blood Cancer Candidate
I-Mab (NASDAQ:IMAB) disclosed in an SEC filing that AbbVie Inc (NYSE:ABBV) would discontinue the global Phase 1b study of lemzoparlimab combination therapy with…